DSpace Repository

The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly

Show simple item record

dc.contributor.author Baştemir, Mehmet.
dc.contributor.author Akin, F.
dc.contributor.author Yaylalı, Güzin Fidan.
dc.date.accessioned 2019-08-16T11:32:25Z
dc.date.available 2019-08-16T11:32:25Z
dc.date.issued 2007
dc.identifier.issn 0028-3835
dc.identifier.uri https://hdl.handle.net/11499/4158
dc.identifier.uri https://doi.org/10.1159/000106830
dc.description.abstract Background/Aim: Despite combined therapy consisting of surgery, external X-ray, and medical therapy, a significant number of acromegaly patients continue to have uncontrolled growth hormone (GH) secretion and active disease. These patients, particularly those with large or invasive tumors, require additional therapy to decrease their GH levels. Our aim was to investigate whether patients with documented GH-secreting pituitary adenomas leading to acromegaly would respond with attenuation of GH and insulin-like growth factor-1 (IGF-1) levels after treatment with a peroxisome proliferator-activated receptor gamma (PPAR-?) agonist. Methods: We conducted prospective analyses in the Endocrinology Clinic of the Pamukkale University. Acromegaly patients who had active disease participated in two admissions: before and after 6 weeks of daily treatment with 8 mg of oral rosiglitazone. Four male and 3 female patients have completed the study. Basal and nadir GH levels during an oral glucose tolerance test were determined, and the IGF-1 and IGF-binding protein-3 levels were also measured both before and 6 weeks after the rosiglitazone treatment. Results: Treatment with rosigitazone did not reduce basal and nadir GH levels during the oral glucose tolerance test and the IGF-1 levels in the patient population as a whole (p > 0.05). Conclusions: The PPAR-? activator rosiglitazone, used at maximum approved dosage, did not reduce plasma GH and IGF-1 levels in patients with acromegaly. Further studies with higher doses and longer duration of PPAR-? agonist administration would be required to determine its usefulness in the treatment in this group of patients. Copyright © 2007 S. Karger AG. en_US
dc.language.iso en en_US
dc.relation.ispartof Neuroendocrinology en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Acromegaly en_US
dc.subject Growth hormone en_US
dc.subject Insulin-like growth factor-1 en_US
dc.subject Peroxisome proliferator-activated receptor gamma en_US
dc.subject Rosiglitazone en_US
dc.subject growth hormone en_US
dc.subject peroxisome proliferator activated receptor gamma agonist en_US
dc.subject rosiglitazone en_US
dc.subject somatomedin binding protein 3 en_US
dc.subject somatomedin C en_US
dc.subject acromegaly en_US
dc.subject adult en_US
dc.subject article en_US
dc.subject clinical article en_US
dc.subject controlled study en_US
dc.subject dose response en_US
dc.subject drug efficacy en_US
dc.subject female en_US
dc.subject hormone blood level en_US
dc.subject human en_US
dc.subject hypophysis adenoma en_US
dc.subject male en_US
dc.subject oral glucose tolerance test en_US
dc.subject priority journal en_US
dc.subject prospective study en_US
dc.subject protein blood level en_US
dc.subject protein expression en_US
dc.subject Adenoma en_US
dc.subject Adult en_US
dc.subject Diabetes Mellitus en_US
dc.subject Female en_US
dc.subject Growth Hormone-Secreting Pituitary Adenoma en_US
dc.subject Human Growth Hormone en_US
dc.subject Humans en_US
dc.subject Hypoglycemic Agents en_US
dc.subject Insulin-Like Growth Factor I en_US
dc.subject Male en_US
dc.subject Middle Aged en_US
dc.subject PPAR gamma en_US
dc.subject Prospective Studies en_US
dc.subject Thiazolidinediones en_US
dc.subject Treatment Failure en_US
dc.title The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly en_US
dc.type Article en_US
dc.identifier.volume 86 en_US
dc.identifier.issue 2 en_US
dc.identifier.startpage 119
dc.identifier.startpage 119 en_US
dc.identifier.endpage 123 en_US
dc.authorid 0000-0003-0012-4700
dc.identifier.doi 10.1159/000106830
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.identifier.pmid 17671378 en_US
dc.identifier.scopus 2-s2.0-34848851961 en_US
dc.identifier.wos WOS:000249722600007 en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record